Cancer’s intrinsic heterogeneity, marked by diverse genetic and epigenetic alterations, contributes significantly to its complexity and resistance to conventional therapies. Traditional treatments such as chemotherapy and radiation often lack specificity, resulting in varied efficacy and substantial systemic toxicity. Personalized cancer therapy aims to overcome these limitations by utilizing detailed molecular profiling to identify actionable genomic alterations tailored to each patient’s unique tumor biology. Advancements in high-throughput sequencing technologies and bioinformatics have facilitated the discovery of critical oncogenic drivers like EGFR mutations in non-small cell lung cancer (NSCLC) and BRAF V600E mutations in melanoma, enabling the development of targeted therapies such as tyrosine kinase inhibitors and monoclonal antibodies. Integrating genomic, transcriptomic, proteomic, and immunophenotyping data provides a comprehensive understanding of tumor biology and the tumor microenvironment, crucial for precise therapeutic interventions. Clinically, personalized approaches have demonstrated improved progression-free survival and overall survival, as seen with agents like crizotinib for ALK-positive NSCLC and trastuzumab for HER2-positive breast cancer. Immunotherapy combined with biomarker-guided patient selection, exemplified by PD-1/PD-L1 inhibitors in mismatch repair-deficient tumors, further illustrates personalized therapy’s potential. However, challenges including tumor heterogeneity, therapeutic resistance driven by on-target mutations and bypass signaling pathways, economic and access barriers to advanced diagnostics and treatments, and regulatory inconsistencies limit widespread adoption. Ongoing developments in molecular diagnostics, immunotherapy, nanotechnology, and digital pathology are poised to enhance the precision and efficacy of cancer treatments. Addressing infrastructural, economic, and regulatory challenges remains critical to fully realize personalized oncology’s promise and to ensure equitable patient access to precision therapies.